Improvement of management tactics for pregnant women with cervical dysplasia, by correcting innate immunity indicators


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To elaborate new approaches to therapy for cervical dysplasia in pregnant women, by correcting the expression of innate immunity factors. Subjects and methods. A study group included 30 patients with cervical dysplasia [low-grade squamous epithelial lesion (TSIT) (43.33%) and high-grade squamous epithelial lesion HSIT (56.67%)]; a comparison group consisted of 11 patients without cervical disease. The patients’ age was 31.6 + 1.7 years in the study group and 31.9 + 2.2 years in the comparison group. Real-time PCR was used to investigate the expression of innate immunity factors (TNF-a, TLR9, TLR2, and HBD-1) in the cervical canal epithelium and in the vagina. The HPV titer was determined using the digene HPV test. Results. During cytokine therapy, there were 1.2- and 1.8-fold reductions in the viral loads of HPV of Groups A9 andA7, respectively. There was a 2-fold increase in the expression of TNF-a and a 10-fold rise in that of NBD-1 and TLR9 and TLR2 in the cervical canal. In the vaginal epithelium, the level of TLR9 increased 5.3-fold. Conclusion. The Syperlymph-induced change in the viral load correlates with innate immunity activation in both the cervical canal mucosa and the vagina due to the activation of the expression of the TIR2 and TIR9 genes and the effector molecules TNF-a and HBD-1.

Full Text

Restricted Access

About the authors

Yulia E. Dobrohotova

N.I. Pirogov Russian National Research Medical University

Email: pr.dobrohotova@mail.ru
MD, professor, head of the Department of obstetrics and gynecology of medical faculty

Lyudmila V. Gankovskaya

N.I. Pirogov Russian National Research Medical University

Email: lvgan@yandex.ru
MD, professor, Leader of Department of Immunology

Ekaterina I. Borovkova

N.I. Pirogov Russian National Research Medical University

Email: Katyanikitina@mail.ru
MD, professor, Department of obstetrics and gynecology of medical faculty

Sofia A. Zalesskaya

N.I. Pirogov Russian National Research Medical University

Email: sofa.zalesskaya@mail.ru
assistant Department of obstetrics and gynecology of medical faculty

Oksana A. Svitich

N.I. Pirogov Russian National Research Medical University; I.I. Mechnikov Research Institute of Vaccines and Sera

Email: svitichoa@yandex.ru
MD, corresponding member of Russian Academy of Sciences, Head of the Laboratory of Molecular Immunology; professor Department of Immunology

Aleksandra B. Filina

I.I. Mechnikov Research Institute of Vaccines and Sera

Email: byzonka@yandex.ru
junior researcher of Laboratory of Molecular Immunology

Elizaveta P. Bistritskaya

I.I. Mechnikov Research Institute of Vaccines and Sera

laboratory assistant researcher of Laboratory of Molecular Immunology

Zulya S. Zaidieva

Maternity Hospital, City Clinical Hospital Forty

Email: dr.zaydieva@mail.ru
PhD, head of clinical diagnostic laboratory

Anna M. Harutyunyan

N.I. Pirogov Russian National Research Medical University

Email: annochka2l.90@mail.ru
post-graduate student Department of obstetrics and gynecology of medical faculty

Irina V. Stepanyants

Maternity Hospital, City Clinical Hospital Forty

Email: apoplexia@rambler.ru
obstetrician-gynecologist

References

  1. Hatem A. Azim Jr., ed. Managing cancer during pregnancy. Springer; 2016. 191p.
  2. Amant F., Halaska M.J., Fumagalli M., Dahl Steffemen K., Lok C., Van Calsteren К. et al. Gynecologic cancers in pregnancy: guideline of a second international consensus meeting. Int. J. Gynecol. Cancer. 2014; 24(3): 394-403.
  3. Tainio K., Athanasiou A., Tikkinen K.A.O., Aaltonen R., Hernândes J.C., Glazer-Livson S. et al. Clinical course of untreated cervical intraepithelial neoplasia grade 2 under active surveillance: systematic review and meta-analysis. BMJ. 2018; 360: k499.
  4. Lee J.M., Lee K.B., Kim Y.T., Ryu H.S., Kim Y.T., Cho C.H. et al. Cervical cancer associated with pregnancy: results of a multicenter retrospective Korean study (KGOG-1006). Am. J. Obstet. Gynecol. 2008; 198(1): 92. el-6.
  5. Wilt T.J., Harris R.P., Qaseem A.; High Value Care Task Force of the American College of Physicians. Screening for cancer: advice for high-value care from the American College of Physicians. Ann. Intern. Med. 2015; 162(10): 718-25.
  6. Mishra B.B., Gundra U.M., Teale J.M. Expression and distribution of Tolllike receptors 11-13 in the brain during murine neurocysticercosis. J. Neuroinflammation. 2008; 5: 53.
  7. McAllum B., Sykes P.H., Sadler L., Macnab H., Simcock B.J., Mekhail A.K. Is the treatment of CIN 2 always necessary in women under 25 years old? Am. J. Obstet. Gynecol. 2011; 205(5): 478. el-7.
  8. Kawai I., Akira S. The role of pattem-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 2010; 11(5): 373-84.
  9. Свитич O.A., Краснопрошина Л.И., Ганковская Л.В., Шибина Л.В., Зайцева И.А. Исследование изменения уровней экспрессии генов TLRs в эпителиальных клетках цервикального канала женщин с воспалительными заболеваниями органов малого таза. Медицинская иммунология. 2015; 17(3): 269-74.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies